Education
About Us
Working with TipRanks
Follow Us
Protalix Biotherapeutics (PLX)
:PLX
Earnings Data
Report Date
Nov 17, 2025TBA (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
0.06Last Year’s EPS
0.03Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted Protalix's significant revenue growth and promising developments in their product pipeline, particularly with Elfabrio and PRX-115. However, challenges such as decreased sales in certain regions, increased R&D expenses, and financial and tax expense increases were noted. Despite these challenges, the overall outlook remains positive due to strong partnerships and market potential.Company Guidance -
Q3 2025
Significant Revenue Increase
Protalix experienced a 50% increase in revenues from selling goods in the first half of 2025 compared to the same period last year, driven primarily by sales of Elfabrio to Chiesi.
Elfabrio Market Potential
Elfabrio is positioned in a global market estimated at USD 2.3 billion in 2025, with expectations to reach USD 3.2 billion by 2030. Protalix anticipates royalties exceeding $100 million by 2030.
Operational Highlights
Protalix has a strong partnership with Chiesi, which has consistently increased its focus on Elfabrio with substantial investments in medical, regulatory, and commercialization programs.
PRX-115 Development Progress
Protalix plans to initiate a Phase II study for their gout product candidate, PRX-115, in the second half of 2025, with promising results from previous studies.
Financial Performance Improvement
The company recorded revenues of $15.4 million for Q2 2025, a 16% increase compared to Q2 2024, and reported a net income of approximately $164,000 compared to a net loss of $2.2 million in Q2 2024.
PLX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PLX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 14, 2025 | $1.61 | $1.52 | -5.59% |
May 09, 2025 | $2.89 | $1.72 | -40.48% |
Mar 17, 2025 | $2.24 | $2.45 | +9.37% |
Nov 14, 2024 | $1.24 | $1.41 | +13.71% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Protalix Biotherapeutics (PLX) report earnings?
Protalix Biotherapeutics (PLX) is schdueled to report earning on Nov 17, 2025, TBA (Confirmed).
What is Protalix Biotherapeutics (PLX) earnings time?
Protalix Biotherapeutics (PLX) earnings time is at Nov 17, 2025, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PLX EPS forecast?
PLX EPS forecast for the fiscal quarter 2025 (Q3) is 0.06.